🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Hematologic Malignancies Demystified 2022: Important Updates in Hematologic Malignancies JANUARY 29, 2022 | FEBRUARY 5, 2022 Register at medscape.org/hemedemystified #HMDlive22 #leusm

Triple combination of quizartinib, decitabine, and venetoclax is currently under investigation in treating FLT3-mutated #AML. Phase I/II results were presented by @musayilmaz54 during #ASH21, find our summary here 👉 loom.ly/1AZlqEg 👈 #leusm #leukemia

Our nation continues to face critical blood shortages & patients with blood cancers are at particularly high risk. Please make it a priority, if able, to donate blood & help save a life. If in #Houston, pls make an appointment MD Anderson Cancer Center Blood Bank today! #EndCancer

A very helpful review on MRD in ALL by @musayilmaz54 Nicholas Short MD Kyaw Z. Hein, MD, MBA! #leusm dovepress.com/clinical-value…

👉👉👉Important new paper from our group led by ⁦Musa Yilmaz, MD⁩ & ⁦Naval Daver, M.D.⁩ ➡️ Hypomethylating agent & venetoclax with #FLT3 inhibitor “triplet” therapy in older/unfit patients w/FLT3 mutated AML | ⁦Blood Cancer Journal⁩ #leusm nature.com/articles/s4140…

Lower intensity chemotherapy combined with a FLT3 inhibitor and venetoclax may be an effective frontline regimen for older patients with FLT3-mutated acute myeloid leukemia, according to the findings of this study. #Leukemia #EndCancer

Published now @BloodCancerJNL 📢 Triplets (LIC+VEN+FLT3i) outperforms doublets (LIC+FLT3i) in frontline older/unfit FLT3m #AML. CR/CRi, MFC negativity, and the 2-year OS rates ➡ 93% vs. 70%, 83% vs. 38%, and 70% vs. 22% 👇 nature.com/articles/s4140… Musa Yilmaz, MD @DaverLeukemia

#JIPOPoll: A 60 yo man is diagnosed w stage 3 DLBCL, germinal center subtype, double hit. Disease progresses after 2 cycles of DA-EPOCH-R. No major medical comorbidities other than HTN. You recommend: Aaron Goodman - “Papa Heme” Sanam Loghavi, MD صنم لغوی 🔬🧬 Naveen Pemmaraju, MD Naval Daver, M.D. Aung Naing Khalid Jazieh

Clinicians who can't accept uncertainty often are unhappy at work, a new study finds. jwat.ch/3mtAiV6

Venetoclax, quizartinib and decitabine resulted in a complete response of 78% in patients with relapsed or refractory FLT3-mutated acute myeloid leukemia in a Phase I/II study. Dr. Musa Yilmaz will present more data at #EHA22: fal.cn/3pkNk Musa Yilmaz, MD #EndCancer

👀 Sneak a peek at the deepest & sharpest infrared image of the early universe ever taken — all in a day’s work for the Webb telescope. (Literally, capturing it took less than a day!) This is Webb’s first image released as we begin to #UnfoldTheUniverse: nasa.gov/webbfirstimage…

Arsenic trioxide 0.15 mg/kg without capping (15 mg maximum dose cap) may cause renal damage in obese patients with APL MD Anderson Cancer Center Wei Ying Jen Tapan Kadia Gautam Borthakur Musa Yilmaz, MD Farhad Ravandi Leukemia & Lymphoma tandfonline.com/doi/full/10.10…

The combination of Quizartinib, Venetoclax and decitabine demonstrated activity in patients who have had three prior treatments for AML, according to results of a clinical trial presented at #ASH23 by our Musa Yilmaz, MD. #EndCancer

Visit #ASH23 booth 122 on Dec. 10 from 11:30 a.m.-12 p.m. to discuss new targets in leukemia treatment with Drs. Naval Daver, Elias Jabbour, Sanam Loghavi and Musa Yilmaz. ASH Naval Daver, M.D. Sanam Loghavi, MD صنم لغوی 🔬🧬 Musa Yilmaz, MD #EndCancer

Our Dr. Musa Yilmaz discusses the most recent update of a study of quizartinib, venetoclax, and decitabine in FLT3-internal tandem duplication mutated acute myeloid leukemia. Watch here: brnw.ch/21wHOFs Targeted Oncology Musa Yilmaz, MD #EndCancer

Musa Yilmaz, MD, Associate Professor in the Department of Leukemia at MD Anderson Cancer Center, discusses an early study of patients with #AML that found a new three-drug combination therapy greatly improved outcomes. Listen to the #podcast here: ow.ly/8MAw50QZUXL Musa Yilmaz, MD

Musa Yilmaz, MD, Associate Professor in the Department of Leukemia at MD Anderson Cancer Center, discusses an early study of patients with #AML that found a new three-drug combination therapy greatly improved outcomes. Listen to the #podcast here: ow.ly/8MAw50QZUXL Musa Yilmaz, MD

Happy Monday, everyone! And if you’re an applicant, have you considered coming to UTHealth Houston Internal Medicine, yes or yes 👁️👄👁️

In this large retrospective study of FLT3-mutated AML, we confirm the important role of FLT3 inhibitors in intensively treated pts and demonstrate promising outcomes w/ low-intensity triplets in older/unfit pts. MD Anderson Cancer Center #Leukemia ACS Journal Cancer doi.org/10.1002/cncr.3…

#EHA2025 #EHA25 Wonderful job 👏 👏 👏 oral presentation at European Hematology Association by our own Musa Yilmaz, MD MD Anderson Cancer Center on DEC/VEN/QUIZ combination for patients w/ #FLT3ITD AML || Sanam Loghavi, MD صنم لغوی 🔬🧬 Naval Daver, M.D.